IRVINE, Calif., Jan. 5, 2012 /PRNewswire/ -- AtheroNova,
(OTCQB: AHRO) ("AtheroNova"), a biotech company focused on the
research and development of compounds to regress atherosclerotic
plaque, announced today that it has appointed Johan M. (Thijs) Spoor as a new member to the
Board of Directors of the Company effective January 3, 2012. Mr. Spoor is an independent
director who will serve on the Audit and Medical Committees of the
Board.
"I am very pleased to strengthen our board with this key
addition," said Thomas W. Gardner,
CEO of AtheroNova. "We are delighted to add an individual to our
Board of Directors with the deep industry experience and the
business acumen that Thijs possesses. His addition will complement
our current Board of Directors and will add further industry
experience. I look forward to the wealth of industry knowledge and
experience that Thijs brings and to his valuable input in shaping
the Company's future as we continue to build AtheroNova."
Mr. Spoor currently serves as the Chief Executive Officer and
President, and is a director, of FluoroPharma Medical, Inc. He
previously held the title of Chief Financial Officer for Sunstone
BioSciences. Prior to joining Sunstone BioSciences, he worked as a
consultant at Oliver Wyman focusing on helping pharmaceutical and
medical device companies evaluate their global revenue potential
given the complex interplay of regulatory approvals, the
reimbursement environment, as well as the impact of physician
preference within constantly evolving standards of care. He further
specialized on the implications of healthcare reform on new product
approval and health insurance reform. Mr. Spoor has also been an
equity research analyst at J.P. Morgan and Credit Suisse covering
the Biotechnology and Medical Device industries. He worked in the
pharmaceutical industry spending 10 years with Amersham / GE
Healthcare where he worked in seven countries in a variety of roles
including setting up GMP facilities meeting ISO 9001 standards,
accountability for the entire nuclear cardiology portfolio and most
recently as the Director of New Product Opportunities leading the
PET strategic plan.
Mr. Spoor holds a Nuclear Pharmacy degree from the University of Toronto as well as an M.B.A. from
Columbia University with concentrations
in finance and accounting. He has been a guest lecturer at
Columbia Business School, Kings College in London and the University of Newcastle in Australia and has presented at medical grand
rounds and psychiatric grand rounds at various hospitals on the
role of brain imaging.
About AtheroNova
AtheroNova Inc. is an early stage biotech company focused on
discovery, research, development and licensing of novel compounds
to reduce or regress atherosclerotic plaque deposits.
Atherosclerotic plaque, which progressively narrows and blocks
arteries, is the main underlying pathology of cardiovascular
disease and the leading cause of death in industrialized nations
worldwide. The Company's focus on compounds to reduce or eliminate
atherosclerotic plaque deposits addresses the most lucrative
segments of the multi-billion dollar prescription drug market:
cardiovascular disease and stroke prevention.
www.atheronova.com.
Forward-Looking Statements
Except for historical information contained herein, the
statements in this release are forward-looking and made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are inherently
unreliable and actual results may differ materially. Examples of
forward looking statements in this news release include statements
regarding the value of Mr. Spoor's appointment to AtheroNova's
board, and the development of applications for AtheroNova's
technology. Factors which could cause actual results to differ
materially from these forward-looking statements include such
factors as significant fluctuations in expenses associated with
clinical trials, failure to secure additional financing, the
inability to complete regulatory filings with the Food and Drug
Administration, the introduction of competing products, or
management's ability to attract and maintain qualified personnel
necessary for the development and commercialization of its planned
products, and other information that may be detailed from time to
time in AtheroNova's filings with the United States Securities and
Exchange Commission. AtheroNova undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
SOURCE AtheroNova